Cost-effectiveness of first-line nivolumab plus ipilimumab combined with two cycles of platinum- doublet chemotherapy compared to four cycles of platinum-doublet chemotherapy in patients with advanced non-small-cell lung cancer in a Dutch healthcare system

Additional Metadata
Keywords	Cost-effectiveness; Partitioned survival model; Non-small cell lung cancer; Immunotherapy
Thesis Advisor	Heine, R.J.S.D.
Persistent URL	hdl.handle.net/2105/61898
Series	Business Economics
Organisation	Erasmus School of Economics
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Jong, A.F. de. (2022, June). Cost-effectiveness of first-line nivolumab plus ipilimumab combined with two cycles of platinum- doublet chemotherapy compared to four cycles of platinum-doublet chemotherapy in patients with advanced non-small-cell lung cancer in a Dutch healthcare system. Business Economics. Retrieved from http://hdl.handle.net/2105/61898

Publication